{ "api_version": "1", "request": { "url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=54", "query": { "intervention": "Placebo once daily", "page": 54 }, "page_size": 10 }, "pagination": { "page": 54, "page_size": 10, "total_count": 5507, "total_pages": 551, "next_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=55&page_size=10", "previous_page_url": "https://clinicaltrialsfind.com/api/v1/search.json?intervention=Placebo+once+daily&page=53&page_size=10" }, "source": "remote", "last_synced_at": "2026-10-29T01:09:48.171Z", "attribution": "Data derived from public ClinicalTrials.gov records. The official record at https://clinicaltrials.gov/ remains the source of truth for current availability, contacts, and full study details.", "notes": [ "This endpoint exposes only public summary fields — no participant contact emails, phone numbers, or scraped investigator contact details.", "For contact information and full protocol detail, follow each trial's `official_url` to the ClinicalTrials.gov record.", "This API is a navigational aid. It does not provide medical advice, eligibility determinations, or compensation guarantees." ], "trials": [ { "nct_id": "NCT01482845", "title": "A Phase 1 Study of the Safety, Tolerability and Pharmacokinetics of ABT-126 in Subjects With Alzheimer's Disease", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Alzheimer's Disease" ], "interventions": [ { "name": "ABT-126", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Abbott", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "55 Years", "maximum_age": "90 Years", "sex": "ALL", "summary": "55 Years to 90 Years" }, "enrollment_count": 20, "start_date": "2011-11", "completion_date": "2012-03", "has_results": false, "last_update_posted_date": "2012-05-02", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 3, "location_summary": "Glendale, California • Hallandale, Florida • Orlando, Florida", "locations": [ { "city": "Glendale", "state": "California" }, { "city": "Hallandale", "state": "Florida" }, { "city": "Orlando", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT01482845" }, { "nct_id": "NCT01883167", "title": "RDEA3170 and Febuxostat Drug Interaction Study", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "RDEA3170 10 mg", "type": "DRUG" }, { "name": "Febuxostat 40 mg", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Ardea Biosciences, Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "18 Years", "maximum_age": "65 Years", "sex": "MALE", "summary": "18 Years to 65 Years · Male only" }, "enrollment_count": 21, "start_date": "2013-06", "completion_date": "2013-12", "has_results": false, "last_update_posted_date": "2014-01-09", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 1, "location_summary": "Kalamazoo, Michigan", "locations": [ { "city": "Kalamazoo", "state": "Michigan" } ], "official_url": "https://clinicaltrials.gov/study/NCT01883167" }, { "nct_id": "NCT00657007", "title": "Phase 1 Study of Belimumab in Subjects With Systemic Lupus Erythematosus (SLE)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Systemic Lupus Erythematosus" ], "interventions": [ { "name": "belimumab", "type": "BIOLOGICAL" }, { "name": "Placebo", "type": "BIOLOGICAL" } ], "intervention_types": [ "BIOLOGICAL" ], "sponsor": "Human Genome Sciences Inc.", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 70, "start_date": "2002-02", "completion_date": "2003-03", "has_results": false, "last_update_posted_date": "2013-08-02", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 18, "location_summary": "Birmingham, Alabama • Los Angeles, California • Washington D.C., District of Columbia + 12 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Los Angeles", "state": "California" }, { "city": "Los Angeles", "state": "California" }, { "city": "Washington D.C.", "state": "District of Columbia" }, { "city": "Chicago", "state": "Illinois" } ], "official_url": "https://clinicaltrials.gov/study/NCT00657007" }, { "nct_id": "NCT00752141", "title": "Cognitive Effects of Oral Oxybutynin and Oxybutynin Chloride Topical Gel in Older Volunteers", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE1" ], "conditions": [ "Healthy Volunteers" ], "interventions": [ { "name": "oxybutynin chloride immediate-release", "type": "DRUG" }, { "name": "oxybutynin chloride topical gel", "type": "DRUG" }, { "name": "placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "Watson Pharmaceuticals", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "60 Years", "maximum_age": "79 Years", "sex": "ALL", "summary": "60 Years to 79 Years" }, "enrollment_count": 153, "start_date": "2008-09", "completion_date": null, "has_results": false, "last_update_posted_date": "2011-09-23", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 6, "location_summary": "Tucson, Arizona • National City, California • Maitland, Florida + 3 more", "locations": [ { "city": "Tucson", "state": "Arizona" }, { "city": "National City", "state": "California" }, { "city": "Maitland", "state": "Florida" }, { "city": "Naples", "state": "Florida" }, { "city": "Ocala", "state": "Florida" } ], "official_url": "https://clinicaltrials.gov/study/NCT00752141" }, { "nct_id": "NCT02066402", "title": "Efficacy and Safety of Intravenous to Oral 6-Day Tedizolid Phosphate vs. Intravenous to Oral 10-Day Linezolid in Patients With Acute Bacterial Skin and Skin Structure Infection (ABSSSI)", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Bacterial Infections" ], "interventions": [ { "name": "Tedizolid (BAY119-2631)", "type": "DRUG" }, { "name": "Placebo Tedizolid (BAY119-2631)", "type": "DRUG" }, { "name": "Linezolid", "type": "DRUG" }, { "name": "Placebo Linezolid", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Bayer", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 598, "start_date": "2014-03-04", "completion_date": "2016-04-18", "has_results": true, "last_update_posted_date": "2017-06-07", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 5, "location_summary": "Chula Vista, California • La Mesa, California • Oceanside, California + 2 more", "locations": [ { "city": "Chula Vista", "state": "California" }, { "city": "La Mesa", "state": "California" }, { "city": "Oceanside", "state": "California" }, { "city": "Las Vegas", "state": "Nevada" }, { "city": "Teaneck", "state": "New Jersey" } ], "official_url": "https://clinicaltrials.gov/study/NCT02066402" }, { "nct_id": "NCT02419612", "title": "A 52-week International, Multicenter Trial With a Long -Term Extension to Evaluate Saxagliptin With Dapagliflozin in Combination With Metformin Compared to Glimepiride in Combination With Metformin in Type 2 Diabetes Who Have Inadequate Glycemic Control on Metformin Alone", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Diabetes" ], "interventions": [ { "name": "Saxagliptin", "type": "DRUG" }, { "name": "Dapagliflozin", "type": "DRUG" }, { "name": "Glimepiride", "type": "DRUG" }, { "name": "Placebo", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "AstraZeneca", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "120 Years", "sex": "ALL", "summary": "18 Years to 120 Years" }, "enrollment_count": 444, "start_date": "2015-08-14", "completion_date": "2019-09-18", "has_results": true, "last_update_posted_date": "2020-06-23", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 22, "location_summary": "Birmingham, Alabama • Chandler, Arizona • Tempe, Arizona + 17 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Chandler", "state": "Arizona" }, { "city": "Tempe", "state": "Arizona" }, { "city": "Huntington Park", "state": "California" }, { "city": "Los Angeles", "state": "California" } ], "official_url": "https://clinicaltrials.gov/study/NCT02419612" }, { "nct_id": "NCT00671567", "title": "Ramelteon in Adults With Chronic Insomnia", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Chronic Insomnia" ], "interventions": [ { "name": "Ramelteon", "type": "DRUG" }, { "name": "Placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Takeda", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": "64 Years", "sex": "ALL", "summary": "18 Years to 64 Years" }, "enrollment_count": 848, "start_date": "2002-12", "completion_date": "2003-09", "has_results": false, "last_update_posted_date": "2012-11-20", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 70, "location_summary": "Birmingham, Alabama • Mobile, Alabama • Mesa, Arizona + 67 more", "locations": [ { "city": "Birmingham", "state": "Alabama" }, { "city": "Mobile", "state": "Alabama" }, { "city": "Mesa", "state": "Arizona" }, { "city": "Phoenix", "state": "Arizona" }, { "city": "Scottsdale", "state": "Arizona" } ], "official_url": "https://clinicaltrials.gov/study/NCT00671567" }, { "nct_id": "NCT00695305", "title": "An Imaging Study in Patients With Atherosclerosis Taking Rilapladib or Placebo for 12 Weeks", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE2" ], "conditions": [ "Atherosclerosis" ], "interventions": [ { "name": "rilapladib", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" }, { "name": "18F Fluorodeoxylucose (FDG)-PET", "type": "OTHER" } ], "intervention_types": [ "DRUG", "OTHER" ], "sponsor": "GlaxoSmithKline", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "50 Years", "maximum_age": "80 Years", "sex": "ALL", "summary": "50 Years to 80 Years" }, "enrollment_count": 83, "start_date": "2008-11", "completion_date": "2010-05", "has_results": false, "last_update_posted_date": "2016-12-01", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 10, "location_summary": "Boston, Massachusetts • Brockton, Massachusetts • Haverhill, Massachusetts + 4 more", "locations": [ { "city": "Boston", "state": "Massachusetts" }, { "city": "Brockton", "state": "Massachusetts" }, { "city": "Haverhill", "state": "Massachusetts" }, { "city": "Linden", "state": "New Jersey" }, { "city": "New York", "state": "New York" } ], "official_url": "https://clinicaltrials.gov/study/NCT00695305" }, { "nct_id": "NCT00359437", "title": "Satavaptan in the Prevention of Ascites Recurrence in Patients With Ascites Due to Cirrhosis of the Liver", "overall_status": "TERMINATED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Ascites", "Liver Cirrhosis" ], "interventions": [ { "name": "Satavaptan", "type": "DRUG" }, { "name": "placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Sanofi", "sponsor_class": "INDUSTRY", "healthy_volunteers": false, "eligibility": { "minimum_age": "18 Years", "maximum_age": null, "sex": "ALL", "summary": "18 Years and older" }, "enrollment_count": 501, "start_date": "2006-07", "completion_date": "2008-10", "has_results": false, "last_update_posted_date": "2016-05-24", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 1, "location_summary": "Malvern, Pennsylvania", "locations": [ { "city": "Malvern", "state": "Pennsylvania" } ], "official_url": "https://clinicaltrials.gov/study/NCT00359437" }, { "nct_id": "NCT01568112", "title": "Effect of Aspirin Pretreatment or Slow Dose Titration on Flushing and Gastrointestinal Events in Healthy Volunteers Receiving Delayed-release Dimethyl Fumarate", "overall_status": "COMPLETED", "study_type": "INTERVENTIONAL", "phases": [ "PHASE3" ], "conditions": [ "Healthy" ], "interventions": [ { "name": "BG00012 (dimethyl fumarate)", "type": "DRUG" }, { "name": "BG00012 placebo", "type": "DRUG" }, { "name": "ASA", "type": "DRUG" }, { "name": "ASA placebo", "type": "DRUG" } ], "intervention_types": [ "DRUG" ], "sponsor": "Biogen", "sponsor_class": "INDUSTRY", "healthy_volunteers": true, "eligibility": { "minimum_age": "25 Years", "maximum_age": "55 Years", "sex": "ALL", "summary": "25 Years to 55 Years" }, "enrollment_count": 173, "start_date": "2012-04", "completion_date": "2012-10", "has_results": true, "last_update_posted_date": "2016-06-13", "last_synced_at": "2026-10-29T01:09:48.171Z", "location_count": 1, "location_summary": "Saint Paul, Minnesota", "locations": [ { "city": "Saint Paul", "state": "Minnesota" } ], "official_url": "https://clinicaltrials.gov/study/NCT01568112" } ] }